On January 14, 2022 I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, reported that the senior management team of the Company, including Founder, Chairman and Acting CEO Dr. Jingwu Zang, President Dr. Andrew Zhu, Chief Financial Officer John Long, Chief Strategy Officer Jielun Zhu and Chief Business Officer Dr. Weimin Tang, have executed the share purchase plan with the open market purchase of over 70,000 of the Company’s American depositary shares ("ADSs") in an aggregate amount of over US$2.6 million as of 14 Jan, 2022 (Press release, I-Mab Biopharma, JAN 14, 2022, View Source [SID1234605493]). The average price per ADS is approximately US$38. The senior management team plans to continue to purchase the Company’s ADSs on the open market for an minimum US$3 million and up to US$20 million on an accumulative basis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!